Enzalutamide | MDV3100 | CAS#915087-33-1 | androgen receptor modulator

MedKoo Cat#: 201821 | Name: Enzalutamide (MDV3100)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Enzalutamide, also known as MDV3100, is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. In August 2012, the United States (U.S.) Food and Drug Administration (FDA) approved enzalutamide for the treatment of castration-resistant prostate cancer.

Chemical Structure

Enzalutamide (MDV3100)

CAS#915087-33-1

Theoretical Analysis

MedKoo Cat#: 201821

Name: Enzalutamide (MDV3100)

CAS#: 915087-33-1

Chemical Formula: C21H16F4N4O2S

Exact Mass: 464.0930

Molecular Weight: 464.43

Elemental Analysis: C, 54.31; H, 3.47; F, 16.36; N, 12.06; O, 6.89; S, 6.90

Price and Availability

Size	Price	Availability
100mg	USD 90.00	Ready to ship
500mg	USD 150.00	Ready to ship
1g	USD 250.00	Ready to ship
2g	USD 450.00	Ready to ship
5g	USD 950.00	Ready to ship
10g	USD 1,650.00	Ready to ship
20g	USD 2,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

MDV3100; MDV 3100; MDV-3100; Enzalutamide brand name: Xtandi.

IUPAC/Chemical Name

4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide

InChi Key

WXCXUHSOUPDCQV-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)

SMILES Code

O=C(NC)C1=CC=C(N(C(N2C3=CC=C(C#N)C(C(F)(F)F)=C3)=S)C(C)(C)C2=O)C=C1F

Appearance

white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

MDV 3100 was found clinically active for metastatic castration-resistant prostate cancer patients in ongoing phase I and II trials. PSA level decreased more than 50 percent in 40/65 chemo-naive patients and 38/75 chemotherapy-treated patients. Recent long-term follow up data from these early clinical studies, announced in February 2011, were positive. Median time to radiographic progression was 56 weeks for chemo-naive patients and 25 weeks for the post-chemotherapy population. Medivation is conducting an international phase III trial that began in September 2009 known as AFFIRM. The trial will determine the effectiveness of MDV3100 in patients who have previously failed chemotherapy treatment with docetaxel. In November 2011, this trial was halted after an interim analysis revealed that patients given the drug lived for approximately 5 months longer than those taking placebo. Medivation is expected to file for FDA approval sometime in 2012. There is another phase III trial, known as PREVAIL, that is investigating the effectiveness of MDV3100 with patients who have not yet received chemotherapy. As of October 2011, this trial is still open to accrual. In addition, a phase II trial began in March 2011 comparing MDV3100 with a commonly used anti-androgen, bicalutamide, in prostate cancer patients who have progressed while on LHRH analogue therapy (e,g., leuprorelin) or surgical castration. For detail see wikipedia.com.

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#T9Z08C26

QC Data

View QC data: current batch, Lot#T9Z08C26

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

AR antagonist with an IC50 of 36 nM in LNCaP prostate cells

In vitro activity:

Myeloid cell function is influenced by their metabolic activity. To investigate whether AR blockade altered metabolism in myeloid cells, MDSCs were generated in vitro in the presence of enzalutamide and metabolic changes were assessed using Seahorse technology. Mitochondrial respiration parameters, such as basal respiration, ATP production from oxidative phosphorylation and maximal respiration, were downregulated in MDSCs treated with enzalutamide when compared to DMSO-treated MDSCs (Figures 4A andB). Enzalutamide treatment led to increased glycolytic rate and reduced glycolytic reserve in MDSCs when compared to DMSO-treated controls (Figures 4C andD). Graphing of ECAR vs. OCR showed increase in ECAR in MDSCs treated with enzalutamide (Figure 4E). WT BMDMs treated in vitro with enzalutamide or BMDMs generated from bone marrow of MARKO mice also exhibited decreased mitochondrial respiration and increased glycolysis (Figure 4F). The metabolic changes induced by enzalutamide were dependent on AR, as treatment of MARKO BMDMs with enzalutamide did not alter these metabolic changes (Figure 4F). In addition, in vitro treatment of tumor-associated CD11b+ cells from human prostate tumor xenografts models PC3M and PCaX led to a similar metabolic shift, indicating that tumor-associated myeloid cell metabolism was altered by AR inhibition (Figures 4G,H). Reference: Cancer Immunol Res. 2020 Sep; 8(9): 1215–1227. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484281/

In vivo activity:

Human bone tumor biopsy studies show that androgen production is present in bone tumors and activation of AR signaling contributes to bone tumor growth. To determine how ERG induced androgen synthesis contributes to bone tumor growth and whether ERG activity can be a predictor for anti-androgen therapy responsiveness, we utilized an intratibial bone tumor growth model with VCaP scr and ERG shRNA cells to address these questions. Tumor growth analysis of both cells lines show that VCaP ERG shRNA cells grow more slowly, requiring 4 weeks longer to reach similar growth sizes as assessed by luciferase imaging (Fig. 3a and d). When both tumors reach comparable size, the animals bearing bone tumors were randomized and treated with vehicle (Tween 80) or Enzalutamide by oral gavage. Tumor growth rate is slower in VCaP shERG tumors compared to scr shRNA tumors (Fig.3b and d). Enzalutamide treatment resulted in significant reduction in tumor burden in VCaP scr shRNA group compared to VCaP shERG group (Fig.3c and d). These data suggest that ERG signaling contributes to bone tumor growth and that AR targeting with enzalutamide significantly inhibits the bone tumor growth presumably through interfering with reduced ERG signaling. References: BMC Cancer. 2019; 19: 972. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802314/

	Solvent	mg/mL	mM
Solubility
	DMSO	50.0	107.66

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 464.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Consiglio CR, Udartseva O, Ramsey KD, Bush C, Gollnick SO. Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell-Mediated Immune Suppression and Tumor Progression. Cancer Immunol Res. 2020 Sep;8(9):1215-1227. doi: 10.1158/2326-6066.CIR-19-0371. Epub 2020 Jul 13. PMID: 32661092; PMCID: PMC7484281. 2. Semaan L, Mander N, Cher ML, Chinni SR. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model. BMC Cancer. 2019 Oct 21;19(1):972. doi: 10.1186/s12885-019-6185-0. PMID: 31638934; PMCID: PMC6802314.

In vitro protocol:

In vivo protocol:

1. Semaan L, Mander N, Cher ML, Chinni SR. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model. BMC Cancer. 2019 Oct 21;19(1):972. doi: 10.1186/s12885-019-6185-0. PMID: 31638934; PMCID: PMC6802314.

1: Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22. PMID: 31329516; PMCID: PMC6839905. 2: Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Czibere A, Fizazi K. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol. 2022 Feb;18(4):425-436. doi: 10.2217/fon-2021-0811. Epub 2022 Jan 26. PMID: 35080190. 3: Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536. PMID: 29949494; PMCID: PMC8288034. 4: Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta- analysis. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):139-148. doi: 10.1038/s41391-021-00395-4. Epub 2021 May 30. Erratum in: Prostate Cancer Prostatic Dis. 2023 Mar 10;: PMID: 34054128; PMCID: PMC9184262. 5: de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D; CARD Investigators. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019 Dec 26;381(26):2506-2518. doi: 10.1056/NEJMoa1911206. Epub 2019 Sep 30. PMID: 31566937. 6: Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15. PMID: 22894553. 7: Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021 Jan;178(2):239-261. doi: 10.1111/bph.15300. Epub 2020 Dec 14. PMID: 33150960. 8: Gao L, Zhang W, Zhang J, Liu J, Sun F, Liu H, Hu J, Wang X, Wang X, Su P, Chen S, Qu S, Shi B, Xiong X, Chen W, Dong X, Han B. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2021 Feb 15;81(4):1026-1039. doi: 10.1158/0008-5472.CAN-20-1965. Epub 2020 Dec 4. PMID: 33277366. 9: Staniszewska M, Fragoso Costa P, Eiber M, Klose JM, Wosniack J, Reis H, Szarvas T, Hadaschik B, Lückerath K, Herrmann K, Fendler WP, Iking J. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. Int J Mol Sci. 2021 Jul 11;22(14):7431. doi: 10.3390/ijms22147431. PMID: 34299051; PMCID: PMC8304389. 10: Shore ND, Renzulli J, Fleshner NE, Hollowell CMP, Vourganti S, Silberstein J, Siddiqui R, Hairston J, Elsouda D, Russell D, Cooperberg MR, Tomlins SA. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol. 2022 Aug 1;8(8):1128-1136. doi: 10.1001/jamaoncol.2022.1641. Erratum in: JAMA Oncol. 2022 Aug 1;8(8):1225. PMID: 35708696; PMCID: PMC9204619. 11: Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017 Feb;71(2):151-154. doi: 10.1016/j.eururo.2016.07.032. Epub 2016 Jul 28. PMID: 27477525; PMCID: PMC5570461. 12: Rodríguez Y, Unno K, Truica MI, Chalmers ZR, Yoo YA, Vatapalli R, Sagar V, Yu J, Lysy B, Hussain M, Han H, Abdulkadir SA. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2022 Jun 6;82(11):2110-2123. doi: 10.1158/0008-5472.CAN-21-3565. PMID: 35405009; PMCID: PMC9177667. 13: Merseburger AS, Attard G, Åström L, Matveev VB, Bracarda S, Esen A, Feyerabend S, Senkus E, López-Brea Piqueras M, Boysen G, Gourgioti G, Martins K, Chowdhury S. Continuous enzalutamide after progression of metastatic castration- resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. Lancet Oncol. 2022 Nov;23(11):1398-1408. doi: 10.1016/S1470-2045(22)00560-5. Epub 2022 Oct 18. PMID: 36265504. 14: Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol. 2020 Sep;78(3):347-357. doi: 10.1016/j.eururo.2020.04.061. Epub 2020 Jun 9. PMID: 32527692. 15: Scott LJ. Enzalutamide: A Review in Castration-Resistant Prostate Cancer. Drugs. 2018 Dec;78(18):1913-1924. doi: 10.1007/s40265-018-1029-9. PMID: 30535926. 16: Pal SK, Stein CA, Sartor O. Enzalutamide for the treatment of prostate cancer. Expert Opin Pharmacother. 2013 Apr;14(5):679-85. doi: 10.1517/14656566.2013.775251. Epub 2013 Feb 27. PMID: 23441761; PMCID: PMC3845878. 17: Sternberg CN. Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. Future Oncol. 2019 May;15(13):1437-1457. doi: 10.2217/fon-2018-0940. Epub 2019 Mar 8. PMID: 30848157. 18: Keating GM. Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer. Drugs Aging. 2015 Mar;32(3):243-9. doi: 10.1007/s40266-015-0248-y. PMID: 25711765. 19: Bennett LL, Ingason A. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer. Ann Pharmacother. 2014 Apr;48(4):530-7. doi: 10.1177/1060028013518899. Epub 2014 Jan 23. PMID: 24458946. 20: Ha YS, Kim IY. Enzalutamide: looking back at its preclinical discovery. Expert Opin Drug Discov. 2014 Jul;9(7):837-45. doi: 10.1517/17460441.2014.918947. Epub 2014 May 12. PMID: 24820058.

1. Zhao Y, Peng X, Baldwin H, Zhang C, Liu Z, Lu X. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model. Biochim Biophys Acta Mol Basis Dis. 2021 Apr 21;1867(7):166151. doi: 10.1016/j.bbadis.2021.166151. Epub ahead of print. PMID: 33892077. 2. Kuo SC, Wang YC, Tan MC, Huang WC, Shiau YR, Wang HY, Lai JF, Huang IW, Lauderdale TL. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. J Antimicrob Chemother. 2021 May 6:dkab141. doi: 10.1093/jac/dkab141. Epub ahead of print. PMID: 33956969. 3. Palit SAL, van Dorp J, Vis D, Lieftink C, Linder S, Beijersbergen R, Bergman AM, Zwart W, van der Heijden MS. A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Sci Rep. 2021 Jul 1;11(1):13683. doi: 10.1038/s41598-021-93107-w. PMID: 34211036; PMCID: PMC8249522. 4. Weber H, Ruoff R, Garabedian MJ. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen. PLoS Genet. 2021 Jan 29;17(1):e1008540. doi: 10.1371/journal.pgen.1008540. PMID: 33513133; PMCID: PMC7875385. 5. Liu G, Jin Z, Lu X. Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib. Int J Mol Sci. 2020 Mar 27;21(7):2337. doi: 10.3390/ijms21072337. PMID: 32230980; PMCID: PMC7178187. 6. Ponnusamy S, He Y, Hwang DJ, Thiyagarajan T, Houtman R, Bocharova V, Sumpter BG, Fernandez E, Johnson D, Du Z, Pfeffer LM, Getzenberg RH, McEwan IJ, Miller DD, Narayanan R. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Clin Cancer Res. 2019 Nov 15;25(22):6764-6780. doi: 10.1158/1078-0432.CCR-19-1458. Epub 2019 Sep 3. PMID: 31481513. 7. Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, Greene S, Zeng Q, Fazli L, Rennie PS, Mills IG, Danielsen H, Theis F, Patterson JB, Jin Y, Saatcioglu F. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat Commun. 2019 Jan 24;10(1):323. doi: 10.1038/s41467-018-08152-3. PMID: 30679434; PMCID: PMC6345973. 8. Palit SA, Vis D, Stelloo S, Lieftink C, Prekovic S, Bekers E, Hofland I, Šuštić T, Wolters L, Beijersbergen R, Bergman AM, Győrffy B, Wessels LF, Zwart W, van der Heijden MS. TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth. Elife. 2019 Dec 19;8:e47430. doi: 10.7554/eLife.47430. PMID: 31855178; PMCID: PMC6968917. 9. Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017 Mar 30;543(7647):728-732. doi: 10.1038/nature21676. Epub 2017 Mar 20. Erratum in: Nature. 2017 May 3;545(7652):116. PMID: 28321130; PMCID: PMC5374023.\ 10. Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, Narayanan R. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Res. 2017 Nov 15;77(22):6282-6298. doi: 10.1158/0008-5472.CAN-17-0976. Epub 2017 Oct 4. PMID: 28978635; PMCID: PMC5890913. 11. Wang Y, Dehigaspitiya DC, Levine PM, Profit AA, Haugbro M, Imberg-Kazdan K, Logan SK, Kirshenbaum K, Garabedian MJ. Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells. Cancer Res. 2016 Sep 1;76(17):5124-32. doi: 10.1158/0008-5472.CAN-16-0385. Epub 2016 Aug 3. PMID: 27488525; PMCID: PMC5010535. 12. Barbier RH, McCrea EM, Lee KY, Strope JD, Risdon EN, Price DK, Chau CH, Figg WD. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. Sci Rep. 2021 May 24;11(1):10765. doi: 10.1038/s41598-021-90143-4. PMID: 34031488; PMCID: PMC8144422. 13. Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate. 2015 Feb 15;75(3):242-54. doi: 10.1002/pros.22910. Epub 2014 Oct 18. PMID: 25327687. 14. Li N, Liu Q, Han Y, Pei S, Cheng B, Xu J, Miao X, Pan Q, Wang H, Guo J, Wang X, Zhang G, Lian Y, Zhang W, Zang Y, Tan M, Li Q, Wang X, Xiao Y, Hu G, Jiang J, Huang H, Qin J. ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat Commun. 2022 Nov 26;13(1):7281. doi: 10.1038/s41467-022-34871-9. PMID: 36435834; PMCID: PMC9701216.